Proton beam therapy and intensity-modulated radiation therapy (IMRT) were found to offer equivalent quality-of-life outcomes for patients with localized prostate cancer, according to data from the PARTIQoL trial. This phase III trial showed no measurable differences between the two approaches in terms of bowel function, urinary symptoms, or sexual function. These findings were presented at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 The results may help inform the decision-making process for localized prostate cancer treatment.
A novel machine learning model may outperform standard statistical models in identifying and stratifying transplantation risk among patients with myelofibrosis, according to a recent study published by Hernández-Boluda et al in Blood.
In a French phase II trial (iNDUCT-GETUG V08) reported in the Journal of Clinical Oncology, Houédé et al found evidence of activity of neoadjuvant durvalumab plus chemotherapy in patients with high-risk, upper-tract urothelial carcinoma.
Breast-conserving therapy, including radiation therapy, could lead to a progressive reduction in breast size over time among women with early-stage breast cancer, according to a recent study published by Becker et al in Plastic and Reconstructive Surgery.
Chemotherapy followed by local excision may be effective in patients with node-negative low rectal adenocarcinoma, according to new findings presented by Buettner et al at the 2025 Society of Surgical Oncology (SSO) Annual Meeting.
Physician burnout has increased significantly in the past decade, and organizational strategies are vital to improve physician well-being, according to new research from ASCO. This compilation includes reports on the state of professional well-being among oncologists in 2023, burnout trends among...
Proton beam therapy and intensity-modulated radiation therapy (IMRT) were found to offer equivalent quality-of-life outcomes for patients with localized prostate cancer, according to data from the PARTIQoL trial. This phase III trial showed no measurable differences between the two approaches in...
On March 10, 2025, the Centers for Medicare & Medicaid Services (CMS) released the Marketplace Integrity and Affordability Proposed Rule aimed at addressing improper enrollments in the Affordable Care Act (ACA) Health Insurance Marketplace. This is the first proposed rule released under the new ...
Arvinas, Inc. and Pfizer Inc. recently announced results from the randomized phase III VERITAC-2 clinical trial (ClinicalTrials.gov identifier NCT05654623) evaluating vepdegestrant monotherapy vs fulvestrant in adults with estrogen receptor–positive, HER2-negative advanced or metastatic breast...
Surgery may not be necessary for patients with early-stage breast cancer who had a complete response to neoadjuvant chemotherapy and standard radiation treatment, according to new data from researchers at The University of Texas MD Anderson Cancer Center. Five-year results from the phase II...
As a Native American and former president of the Seneca Nation of Indians, I am keenly aware of the disparities in cancer care we face in accessing screening and treatment, which results in worse survival rates compared with those of racial and ethnic populations.1 Native American and Alaska Native ...
An increasing proportion of the U.S. public may be aware of the link between consuming alcohol and the elevated risk of later developing cancer, according to a recent survey conducted by the University of Pennsylvania’s Annenberg Public Policy Center (APPC). Background On January 3, 2025, Vivek...